ANDA 203276, held by Avet Lifesciences. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 203276 (Doxycycline Hyclate), held by Avet Lifesciences, was first approved by FDA on Feb 19, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 19, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE/VIAL ยท injectable;injection | Doxycycline Hyclate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters